sub:assertion {
d:DB00015 v:identifier "DB00015" ;
v:namespace "drugbank" ;
v:uri "http://bio2rdf.org/drugbank:DB00015" ;
v:x-identifiers.org <
http://identifiers.org/drugbank/DB00015> ;
dv:drugbank-id "BIOD00013" , "BTD00013" , "DB00015" ;
dv:x-atc <
http://bio2rdf.org/atc:B01AD07> ;
dv:x-cas <
http://bio2rdf.org/cas:133652-38-7> ;
dv:x-dpd <
http://bio2rdf.org/dpd:2233013> ;
dv:x-genbank <
http://bio2rdf.org/genbank:L00153> ;
dv:x-ndc <
http://bio2rdf.org/ndc:24477-041-02> ;
dv:x-pharmgkb <
http://bio2rdf.org/pharmgkb:PA164743728> ;
dv:x-uniprot <
http://bio2rdf.org/uniprot:P00750> ;
dv:x-wikipedia <
http://bio2rdf.org/wikipedia:Reteplase> ;
dct:description "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF)."@en ;
dct:identifier "drugbank:DB00015" ;
dct:title "Reteplase"@en ;
a dv:Drug ;
rdfs:label "Reteplase [drugbank:DB00015]"@en ;
rdfs:seeAlso <
http://www.drugbank.ca/drugs/DB00015> , <
http://www.drugs.com/cdi/reteplase.html> , <
http://www.rxlist.com/cgi/generic2/reteplase.htm> .
}